Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2006 May 31;6(3):174–181. doi: 10.1016/S1045-1870(05)80045-7

Infections in cystic fibrosis

Kathy A Marks-Austin 1,2,3, Stanley B Fiel 1,2,3, Preston W Campbell 1,2,3,*, Terrence L Stull 1,2,3
PMCID: PMC7129642  PMID: 32288449

The content is available as a PDF (727.0 KB).

References

  • 1.FitzSimmons SC. Cystic Fibrosis Foundation Patient Registry Annual Data Report. 1993 [Google Scholar]
  • 2.Rommens JM, Iannuzzi MC, Kerem B. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science. 1989;245:1059–1064. doi: 10.1126/science.2772657. [DOI] [PubMed] [Google Scholar]
  • 3.Kerem B, Rommens JM, Buchanan JA. Identification of the cystic fibrosis gene: Genetic analysis. Science. 1989;245:1073–1080. doi: 10.1126/science.2570460. [DOI] [PubMed] [Google Scholar]
  • 4.Riordan JR, Rommens JM, Kerem B. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–1073. doi: 10.1126/science.2475911. [DOI] [PubMed] [Google Scholar]
  • 5.Anderson MP, Rich DP, Gregory RJ. Generation of cAMP-activated chloride currents by expression of CFTR. Science. 1991;251:679–682. doi: 10.1126/science.1704151. [DOI] [PubMed] [Google Scholar]
  • 6.Cotton CU, Stutts MJ, Knowles MR. Abnormal apical cell membrane in cystic fibrosis respiratory epithelium: An in vitro electrophysiologic analysis. J Clin Invest. 1987;79:80–85. doi: 10.1172/JCI112812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Knowles MR, Stutts MJ, Spock A. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science. 1983;221:1067–1070. doi: 10.1126/science.6308769. [DOI] [PubMed] [Google Scholar]
  • 8.Waltner WE, Boucher RC, Gatzy T. Pharmacotherapy of airway disease in cystic fibrosis. Trends Pharmacol Sci. 1987;8:316–320. [Google Scholar]
  • 9.Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet. 1993;341:1065–1069. doi: 10.1016/0140-6736(93)92422-p. [DOI] [PubMed] [Google Scholar]
  • 10.Wood RE, Boat TF, Doershuk CF. Cystic fibrosis: State of the art. Am Rev Respir Dis. 1976;113:533–578. doi: 10.1164/arrd.1976.113.6.833. [DOI] [PubMed] [Google Scholar]
  • 11.Rosenfeld M, Ramsey B. Evolution of airway microbiology in the infant with cystic fibrosis: Role of nonpseudomonal and pseudomonal pathogens. Semin Respir Infect. 1992;7(3):158–167. [PubMed] [Google Scholar]
  • 12.Chartrand SA, Marks MI. Pulmonary infections in cystic fibrosis: Pathogenesis and therapy. In: Pennington JE, editor. Respiratory Infections: Diagnosis and Management. Raven; New York, NY: 1989. pp. 276–297. [Google Scholar]
  • 13.FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122:1–9. doi: 10.1016/s0022-3476(05)83478-x. [DOI] [PubMed] [Google Scholar]
  • 14.Albus A, Fournier JM, Wolz C. Staphylococcus aureus capsular types and antibody response to lung infections in patients with cystic fibrosis. J Clin Microbiol. 1988;26:2505–2509. doi: 10.1128/jcm.26.12.2505-2509.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Anderson DH. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics. 1949;3:406–417. [PubMed] [Google Scholar]
  • 16.May JR, Roberts DE. Bronchial infection in cystic fibrosis. Lancet. 1969;1:602–603. doi: 10.1016/s0140-6736(69)91536-0. [DOI] [PubMed] [Google Scholar]
  • 17.Loening-Baucke VA, Mischler E, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr. 1979;95:630–637. doi: 10.1016/s0022-3476(79)80785-4. [DOI] [PubMed] [Google Scholar]
  • 18.Marks MI. Clinical significance of Staphylococcus aureus in cystic fibrosis. Infection. 1990;18:53–56. doi: 10.1007/BF01644186. [DOI] [PubMed] [Google Scholar]
  • 19.Watson KC, Kerr EJC, Baillie M. Temporal changes in biotypes of Haemophilus influenzae isolated from patients with cystic fibrosis. J Med Microbiol. 1988;26:129–132. doi: 10.1099/00222615-26-2-129. [DOI] [PubMed] [Google Scholar]
  • 20.Rayner RJ, Hiller EJ, Ispahani P. Haemophilus infection in cystic fibrosis. Arch Dis Child. 1990;65:255–258. doi: 10.1136/adc.65.3.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Long SS, Teter MJ, Gilligan PH. Biotype of Haemophilus influenzae: Correlation with virulence and ampicillin resistance. J Infect Dis. 1983;147:800–806. doi: 10.1093/infdis/147.5.800. [DOI] [PubMed] [Google Scholar]
  • 22.Doggett RG. Incidence of mucoid Pseudomonas aeruginosa from clinical sources. Appl Microbiol. 1969;18:936–937. doi: 10.1128/am.18.5.936-937.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mearns MB. Natural history of pulmonary infections in cystic fibrosis. In: Sturgess JM, editor. Perspectives in Cystic Fibrosis. Canadian Cystic Fibrosis Foundation; Toronto, Canada: 1980. pp. 325–334. [Google Scholar]
  • 24.Govan JRW. Alginate biosynthesis and other unusual characteristics associated with the pathogenesis of Pseudomonas aeruginosa in cystic fibrosis. In: Griffiths E, Donachie WE, Stephen J, editors. Bacterial Infections of Respiratory and Gastrointestinal Mucosae. IRL Press; Oxford: 1988. pp. 67–96. [Google Scholar]
  • 25.Marrie TJ, Harding GK, Ronald AR. Influence of mucoidy on antibody coating of Pseudomonas aeruginosa. J Infect Dis. 1979;139:357–361. doi: 10.1093/infdis/139.3.357. [DOI] [PubMed] [Google Scholar]
  • 26.Ramphal R, Pier GB. Role of Pseudomonas aeruginosa mucoid exopolysaccharide in adherence to tracheal cells. Infect Immun. 1985;47:1–4. doi: 10.1128/iai.47.1.1-4.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.May TB, Shinabarger D, Maharj R. Alginate synthesis by Pseudomonas aeruginosa: A key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev. 1991;4:191–206. doi: 10.1128/cmr.4.2.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Marshall BC, Carroll KC. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis. Semin Respir Infect. 1991;6:11–18. [PubMed] [Google Scholar]
  • 29.Fomsgaard A, Conrad RS, Gulanos C. Comparative immunochemistry of lipopolysaccharides from typable and polyagglutinable Pseudomonas aeriginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol. 1988;26:821–826. doi: 10.1128/jcm.26.5.821-826.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fick RB, Jr, Naegel GP, Matthay RA. Cystic fibrosis Pseudomonas opsonins: Inhibitory nature in an in vitro phagocytic assay. J Clin Invest. 1981;68:899–914. doi: 10.1172/JCI110345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Kerem E, Corey M, Stein R. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr Infect Dis J. 1990;9:494–498. doi: 10.1097/00006454-199007000-00008. [DOI] [PubMed] [Google Scholar]
  • 32.Doring G, Hoiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983;42:197–201. doi: 10.1128/iai.42.1.197-201.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Winnie GB, Cowan RG. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: Correlation between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol. 1991;10:92–100. doi: 10.1002/ppul.1950100210. [DOI] [PubMed] [Google Scholar]
  • 34.Hoiby N, Pedersen SS. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Pediatr Scand. 1989;78:395–404. doi: 10.1111/j.1651-2227.1989.tb11099.x. [DOI] [PubMed] [Google Scholar]
  • 35.Langord D, Hiller J. Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis: Three year result. Arch Dis Child. 1984;59:1131–1134. doi: 10.1136/adc.59.12.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Miller JU, Spilsbury FF, Jones RJ. A new polyvalent Pseudomonas vaccine. J Med Microbiol. 1974;10:19–27. doi: 10.1099/00222615-10-1-19. [DOI] [PubMed] [Google Scholar]
  • 37.Pennington JE, Reynolds HY, Wood RE. Use of Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am J Med. 1975;58:629–636. doi: 10.1016/0002-9343(75)90498-2. [DOI] [PubMed] [Google Scholar]
  • 38.Cryz SJ, Jr, Wedgwood J, Lang AB. Immunizatin of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J Infect Dis. 1994;169:1159–1162. doi: 10.1093/infdis/169.5.1159. [DOI] [PubMed] [Google Scholar]
  • 39.Pier GB, DesJardin D, Grout M. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect Immun. 1994;62:3972–3979. doi: 10.1128/iai.62.9.3972-3979.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by carly treatment. Lancet. 1991;338:725–726. doi: 10.1016/0140-6736(91)91446-2. [DOI] [PubMed] [Google Scholar]
  • 41.Rosenstein BJ, Hall DE. Pneumonia and septicemia due to Pseudomonas cepacia in a patient with cystic fibrosis. Johns Hopkins Med J. 1980;147:188–189. [PubMed] [Google Scholar]
  • 42.Isles A, Maclusky I, Corey M. Pseudomonas cepacia infection in cystic fibrosis: An emerging problem. J Pediatr. 1984;104:206–210. doi: 10.1016/s0022-3476(84)80993-2. [DOI] [PubMed] [Google Scholar]
  • 43.Lewin LO, Byard PJ, Davis PB. Effect of Pseudomonas cepacia colonization in survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol. 1990;43:125–131. doi: 10.1016/0895-4356(90)90175-o. [DOI] [PubMed] [Google Scholar]
  • 44.Tablan OC, Chorba TL, Schidlow DV. Pseudomonas cepacia colonization in patients with cystic fibrosis. J Pediatr. 1985;107:382–387. doi: 10.1016/s0022-3476(85)80511-4. [DOI] [PubMed] [Google Scholar]
  • 45.Tablan OC, Martone WJ, Doershuk CF. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: Risk factors and outcomes. Chest. 1987;91:527–532. doi: 10.1378/chest.91.4.527. [DOI] [PubMed] [Google Scholar]
  • 46.LiPuma JJ, Dasen SE, Nielson DW. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990;336:1094–1096. doi: 10.1016/0140-6736(90)92571-x. [DOI] [PubMed] [Google Scholar]
  • 47.Smith DI, Gumery LB, Smith EG. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: Evidence of person-to-person transmission. J Clin Microbiol. 1993;31:3017–3022. doi: 10.1128/jcm.31.11.3017-3022.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.LiPuma JJ, Marks-Austin KA, Holsclaw D. Inapparent, high-frequency transmission of Pseudomonas cepacia among cystic fibrosis patients. J Pediatr Infect Dis. 1994;13:716–719. doi: 10.1097/00006454-199408000-00007. [DOI] [PubMed] [Google Scholar]
  • 49.Kostman JR, Edlind TD, LiPuma JJ. Molecular epidemiology of Pseudomonas cepacia determined by polymerase chain reaction ribotyping. J Clin Microbiol. 1992;30:2084. doi: 10.1128/jcm.30.8.2084-2087.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Heidt A, Monteil H, Richard C. O and H serotyping of Pseudomonas cepacia. J Clin Microbiol. 1983;18:738–740. doi: 10.1128/jcm.18.3.738-740.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Prince A. Antibiotic resistance of Pseudomonas species. J Pediatr. 1986;108:830–834. doi: 10.1016/s0022-3476(86)80753-3. [DOI] [PubMed] [Google Scholar]
  • 52.Pugliese G, Lichtenberg DA. Nosocomial bacterial pneumonia: An overview. Am J Infect Control. 1987;15:249–265. doi: 10.1016/0196-6553(87)90119-2. [DOI] [PubMed] [Google Scholar]
  • 53.Villarino ME, Stevens LE, Schable B. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol. 1992;13:201–206. doi: 10.1086/646510. [DOI] [PubMed] [Google Scholar]
  • 54.Marshall WF, Keating MR, Anhalt JP. Xanthomonas maltophilia: An emerging nosocomial pathogen. Mayo Clin Pro. 1989;64:1097–1104. doi: 10.1016/s0025-6196(12)64979-9. [DOI] [PubMed] [Google Scholar]
  • 55.Klinger JD, Thomassen MJ. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis. 1985;3:149–158. doi: 10.1016/0732-8893(85)90025-2. [DOI] [PubMed] [Google Scholar]
  • 56.Bauernfeind A, Bertele RM, Harms K. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection. 1987;15:270–277. doi: 10.1007/BF01644137. [DOI] [PubMed] [Google Scholar]
  • 57.Lecso-Bornet M, Pierre J, Sarkis-Karam D. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother. 1992;36:669–671. doi: 10.1128/aac.36.3.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Mett H, Rosta S, Schacher B. Outer membrane permeability and beta-lactamase content in Pseudomonas maltophilia clinical isolates and laboratory mutants. Rev Infect Dis. 1988;10:765–769. doi: 10.1093/clinids/10.4.765. [DOI] [PubMed] [Google Scholar]
  • 59.Yu VL, Rumans LW, Wing EF. Pseudomonas maltophilia causing heroin-associated infective endocarditis. Arch Intern Med. 1978;138:1667–1671. [PubMed] [Google Scholar]
  • 60.Morrison AJ, Jr, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol. 1986;24:52–55. doi: 10.1128/jcm.24.1.52-55.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Hoiby N, Hoff GE, Jersen K. Serological types of Diplococcus pneumoniae isolated from the respiratory tract of children with cystric fibrosis and children with other diseases. Scand J Respir Dis. 1976;57:37–40. [PubMed] [Google Scholar]
  • 62.Efthimiou J, Hodson ME, Taylor P. Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis. Thorax. 1984;39:150–154. doi: 10.1136/thx.39.2.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Tenover FC, Edelstein PH, Goldstein LG. Comparison of cross-staining reactions by Pseudomonas spp. and flourescein-labeled polyclonal and monoclonal antibodies directed against Leginella pneumophilia. J Clin Microbiol. 1986;23:647–649. doi: 10.1128/jcm.23.3.647-649.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Hjelte L, Petrini B, Kallenius G. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax. 1990;45:397–400. doi: 10.1136/thx.45.5.397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Efthimiou J, Smith MJ, Hodson ME. Fatal pulmonary infection with mycobacyerium fortuitum in cystic fibrosis. Br J Dis Chest. 1984;78:299–302. [PubMed] [Google Scholar]
  • 66.Smith MJ, Efthimiou J, Hodson ME. Mycobacterial isolations in young adults with cystic fibrosis. Thorax. 1984;39:369–375. doi: 10.1136/thx.39.5.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. J Pediatric. 1980;96:689–691. doi: 10.1016/s0022-3476(80)80743-8. [DOI] [PubMed] [Google Scholar]
  • 68.Hoiby N. Microbiology of lung infection in cystic fibrosis patients. Acta Paediatr Scand Suppl. 1982;301:33–54. [Google Scholar]
  • 69.Aitken ML, Burke W, McDonald G. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest. 1993;103:1096–1099. doi: 10.1378/chest.103.4.1096. [DOI] [PubMed] [Google Scholar]
  • 70.Kilby J, Gilligan P, Yankaskas JR. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest. 1992;102:70–75. doi: 10.1378/chest.102.1.70. [DOI] [PubMed] [Google Scholar]
  • 71.Whittier S, Hopfer RL, Knowles MR. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol. 1993;31:861–864. doi: 10.1128/jcm.31.4.861-864.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Kinney JS, Little BJ, Yolken RH. Mycobacterium avium complex in a patient with cystic fibrosis: Disease vs. colonization. Pediatr Infect Dis J. 1989;8:393–396. doi: 10.1097/00006454-198906000-00013. [DOI] [PubMed] [Google Scholar]
  • 73.Przyklenk B, Bauernfeind A, Horl G. Serologic response to Candida albicans and Aspergillus fumigatus in cystic fibrosis. Infection. 1987;15:308–310. doi: 10.1007/BF01644143. [DOI] [PubMed] [Google Scholar]
  • 74.Mearns M, Longbottom J, Batten J. Precipitating antibodies to Aspergillus fumigatus in cystic fibrosis. Lancet. 1967;1:538–539. doi: 10.1016/s0140-6736(67)92115-0. [DOI] [PubMed] [Google Scholar]
  • 75.Knutsen A, Slavin RG. Allergic bronchopulmonary mycosis complicating cystic fibrosis. Semin Respir Infect. 1992;7:179–192. [PubMed] [Google Scholar]
  • 76.Petersen NT, Hoiby N, Mordhorst CH. Respiratory infections in cystic fibrosis patients caused by virus, Chlamydia and Mycoplasma—Possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981;70(5):623–628. doi: 10.1111/j.1651-2227.1981.tb05757.x. [DOI] [PubMed] [Google Scholar]
  • 77.Carson J, Collier AM, Hu SS. Acquired ciliary defects in nasal epithelium of children with acute viral upper respiratory infections. N Engl J Med. 1985;312:463–468. doi: 10.1056/NEJM198502213120802. [DOI] [PubMed] [Google Scholar]
  • 78.Hall CB, Hall WJ, Gala CJ. Long term prospective study in children after respiratory syncytial virus infection. J Pediatr. 1984;105:358–364. doi: 10.1016/s0022-3476(84)80005-0. [DOI] [PubMed] [Google Scholar]
  • 79.Prober CG. The impact of respiratory viral infections in patients with cystic fibrosis. Clin Rev Allergy. 1991;9:87–102. doi: 10.1007/978-1-4612-0475-6_6. [DOI] [PubMed] [Google Scholar]
  • 80.Wright PF, Khaw KT, Oxman MN. Evaluation of the safety of amantadine-HCl and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis. 1976;134:144–149. doi: 10.1093/infdis/134.2.144. [DOI] [PubMed] [Google Scholar]
  • 81.Abman SH, Ogle JW, Butler-Simon N. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113:826–830. doi: 10.1016/s0022-3476(88)80008-8. [DOI] [PubMed] [Google Scholar]
  • 82.Winnie GB, Cowan RG. Association of Epstein-Barr virus infection and pulmonary exacerbations in patients with cystic fibrosis. Pediatr Infect Dis J. 1992;11:722–726. doi: 10.1097/00006454-199209000-00010. [DOI] [PubMed] [Google Scholar]
  • 83.Pribble CG, Black PG, Bosso LA. Clinical manifestations of exacerbations of cystic fibrosis associated with non-bacterial infections. J Pediatr. 1990;117:200–204. doi: 10.1016/S0022-3476(05)80530-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Wang EE, Prober CG, Manson B. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984;311:1653–1658. doi: 10.1056/NEJM198412273112602. [DOI] [PubMed] [Google Scholar]
  • 85.Smith AL, Redding G, Doershuk C. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr. 1988;112:547–554. doi: 10.1016/s0022-3476(88)80165-3. [DOI] [PubMed] [Google Scholar]
  • 86.Ramsey BW, Wentz KR, Smith AL. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis. 1991;144:331–337. doi: 10.1164/ajrccm/144.2.331. [DOI] [PubMed] [Google Scholar]
  • 87.Iacocca VF, Sibinga M, Barbero G. Respiratory tract bacteriology in cystic fibrosis. Am J Dis Child. 1963;106:115–124. doi: 10.1001/archpedi.1963.02080050317012. [DOI] [PubMed] [Google Scholar]
  • 88.Saiman L, Niu WW, Heu HC. Antibiotic strategies to treat multi-resistant Pseudomonas aeruginosa. Program and Papers of the 6th Annual North American Cystic Fibrosis Conference; Washington, DC; 1992. (abstr 191) [Google Scholar]
  • 89.de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis: Differences and clinical significance. Clin Pharmacokinet. 1987;13:228–253. doi: 10.2165/00003088-198713040-00002. [DOI] [PubMed] [Google Scholar]
  • 90.Grenier B. Use of the quinolones in cystic fibrosis. Rev Infect Dis. 1989;11(suppl 5):S1245–S1252. doi: 10.1093/clinids/11.supplement_5.s1245. [DOI] [PubMed] [Google Scholar]
  • 91.Goldfarb J, Stern RC, Reed MD. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med. 1987;82:174–178. [PubMed] [Google Scholar]
  • 92.Scully BE, Nakatomi M, Ores C. Ciprofloxacin therapy in cystic fibrosis. Am J Med. 1987;82:196–200. [PubMed] [Google Scholar]
  • 93.Potter JL, Spector S, Matthews LW. Studies in pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am Rev Respir Dis. 1969;99:909–916. doi: 10.1164/arrd.1969.99.6.909. [DOI] [PubMed] [Google Scholar]
  • 94.Elmes PC, White JC. Deoxyribonuclease in treatment of purulent bronchitis. Thorax. 1953;8:295–300. doi: 10.1136/thx.8.4.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis. 1968;98:597–598. doi: 10.1164/arrd.1968.98.4.697. [DOI] [PubMed] [Google Scholar]
  • 96.Shak S, Capon DJ, Hellmiss R. Vol. 87. 1990. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum; pp. 9188–9192. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Aitken ML, Burke W, McDonald G. Recombinant humane DNase inhalation in normal subjects and patients with cystic fibrosis: A phase I study. JAMA. 1992;267:1947–1951. [PubMed] [Google Scholar]
  • 98.Hubbard RC, McElvaney NG, Birrer P. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992;326:812–815. doi: 10.1056/NEJM199203193261207. [DOI] [PubMed] [Google Scholar]
  • 99.Ramsey BW, Astley SJ, Aitken MJ. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993;148:145–151. doi: 10.1164/ajrccm/148.1.145. [DOI] [PubMed] [Google Scholar]
  • 100.Fuchs HJ, Borowitz DS, Christiansen DH. Effect of acrosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331:637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
  • 101.Maclusky I, Levison H, Gold R. Inhaled antibiotics in cystic fibrosis: Is there a therapeutic effect? J Pediatr. 1986;108:861–865. doi: 10.1016/s0022-3476(86)80758-2. [DOI] [PubMed] [Google Scholar]
  • 102.Cooney GF, Lum BL, Tomaselli M. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol. 1994;34:255–259. doi: 10.1002/j.1552-4604.1994.tb03995.x. [DOI] [PubMed] [Google Scholar]
  • 103.Auerbach HS, Williams M, Kirkpatrick JA. Alternate-day prednisone reduces morbidity and improves pulmonary function cystic fibrosis. Lancet. 1985;2:686–688. doi: 10.1016/s0140-6736(85)92929-0. [DOI] [PubMed] [Google Scholar]
  • 104.Rosenstein FJ, Eigen H. Risks of alternate day prednisone in patients with cystic fibrosis. Pediatrics. 1991;87:245–246. [PubMed] [Google Scholar]
  • 105.Konstan MW, Hoppel CL, Chai B. Ibuprofen in children with cystic fibrosis: Pharmacokinetics and adverse effects. J Pediatr. 1991;118:956–964. doi: 10.1016/s0022-3476(05)82218-8. [DOI] [PubMed] [Google Scholar]
  • 106.Konstan MW, Byard PJ, Hoppel CL. Effects of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848–854. doi: 10.1056/NEJM199503303321303. [DOI] [PubMed] [Google Scholar]
  • 107.Winnie GB, Cowan RG, Wade NA. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. J Pediatr. 1989;114:309–314. doi: 10.1016/s0022-3476(89)80804-2. [DOI] [PubMed] [Google Scholar]
  • 108.Knowles MR, Church NL, Waltner WE. A pilot study of aerosolized amiloride for treatment of lung disease in cystic fibrosis. N Engl J Med. 1990;322:1189–1194. doi: 10.1056/NEJM199004263221704. [DOI] [PubMed] [Google Scholar]
  • 109.Zabner R, Quinn JP. Antimicrobials in cystic fibrosis: Emergence of resistance and implications for treatment. Semin Respir Infect. 1992;7:210–217. [PubMed] [Google Scholar]
  • 110.McLaughlin FJ, Matthews WJ, Strieder DJ. Clinical and bacteriological responses to three antibiotics regimens for acute exacerbation of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983;147:559–567. doi: 10.1093/infdis/147.3.559. [DOI] [PubMed] [Google Scholar]
  • 111.Nelson JW, Doherty CJ, Brown PH. Pseudomonas cepacia in patients with cystic fibrosis. Lancet. 1991;338:1525. doi: 10.1016/0140-6736(91)92342-y. [DOI] [PubMed] [Google Scholar]
  • 112.Govan JRW, Brown PH, Maddison J. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet. 1993;342:15–19. doi: 10.1016/0140-6736(93)91881-l. [DOI] [PubMed] [Google Scholar]
  • 113.Tummler B, Koopmann U, Grothues D. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991;29:1265–1267. doi: 10.1128/jcm.29.6.1265-1267.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Shennib H, Adomie R, Noirclerc M. Current status of cystic fibrosis lung transplant. Arch Intern Med. 1992;152:1585–1588. [PubMed] [Google Scholar]
  • 115.Snell GI, de Hoyos A, Krajden M. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest. 1993;103:466–471. doi: 10.1378/chest.103.2.466. [DOI] [PubMed] [Google Scholar]

Articles from Seminars in Pediatric Infectious Diseases are provided here courtesy of Elsevier

RESOURCES